CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

Conference Correspondent  - SABCS 2017 - Breast Cancer, Breast Cancer, Video
Hope S. Rugo, MD
Despite international guidelines and data that show CDK4/6 inhibitors plus aromatase inhibitors can improve overall response rates, overall survival, and progression-free survival in patients with metastatic breast cancer, there is a lasting belief among patients that chemotherapy is the preferable course of treatment. Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy.
Related Items
Explaining Treatment Regimens to Patients with HR+/HER2- Metastatic Breast Cancer
Thomas Bachelot, MD, PhD
Video Library published on July 19, 2018 in Breast Cancer, Video
HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms
Hope S. Rugo, MD
Video Library published on July 19, 2018 in Breast Cancer, Video
Giving People Hope as an Oncology Nurse
Laura Mulderrig, BSN, RN, OCN
Video Library published on May 18, 2018 in ONE Award, Video
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
Rebecca Bailey
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Breast Cancer, Immunotherapy
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TON Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only, In the News
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Breast Cancer, Drug Updates & News, ESMO
Blood-Based Biopsy Can Predict Breast Cancer Recurrence
TON Web Exclusives published on February 26, 2018 in Breast Cancer
The Benefit of CDK4/6 Inhibitors Applies Equally to Older Women with Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
Last modified: December 7, 2017